Description: UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Home Page: www.urogen.com
URGN Technical Analysis
400 Alexander Park
Princeton,
NJ
08540
United States
Phone:
646 768 9780
Officers
Name | Title |
---|---|
Ms. Elizabeth A. Barrett | Pres, CEO & Director |
Mr. Jason Drew Smith | Gen. Counsel, Chief Compliance Officer & Corp. Sec. |
Dr. Mark P. Schoenberg M.D. | Chief Medical Officer |
Mr. Dong Kim | Chief Financial Officer |
Vincent I. Perrone | Sr. Director of Investor Relations |
Eric Van Zanten | Sr. Director of Communications |
Dr. Sari Prutchi-Sagiv Ph.D. | Marketing Director |
Dr. Marina Konorty | Exec. VP of R&D and Technical Operations |
Mr. Jeffrey Bova M.B.A. | Chief Commercial Officer |
Mr. James Ottinger R.ph. | Exec. VP of Regulatory Affairs & Quality |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 16.0495 |
Price-to-Sales TTM: | 2.9251 |
IPO Date: | 2017-05-04 |
Fiscal Year End: | December |
Full Time Employees: | 195 |